The P53 pathway: what questions remain to be explored?

The p53 pathway is composed of hundreds of genes and their products that respond to a wide variety of stress signals. These responses to stress include apoptosis, cellular senescence or cell cycle arrest. In addition the p53-regulated genes produce proteins that communicate these stress signals to adjacent cells, prevent and repair damaged DNA and create feedback loops that enhance or attenuate p53 activity and communicate with other signal transduction pathways. Many questions remain to be explored in our understanding of how this network of genes plays a role in protection from cancers, therapy and integrating the homeostatic mechanisms of stress management and fidelity in a cell and organism. The goal of this chapter is to elucidate some of those questions and suggest new directions for this area of research.

[1]  W. Tan,et al.  The role of P53 and MDM2 polymorphisms in the risk of esophageal squamous cell carcinoma. , 2005, Cancer research.

[2]  Delin Chen,et al.  Mammalian SIRT1 Represses Forkhead Transcription Factors , 2004, Cell.

[3]  A. Levine,et al.  The coordinate regulation of the p53 and mTOR pathways in cells. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[4]  S. Lowe,et al.  Tumor suppression by Ink4a-Arf: progress and puzzles. , 2003, Current opinion in genetics & development.

[5]  W. Deppert,et al.  Transcription-independent pro-apoptotic functions of p53. , 2005, Current opinion in cell biology.

[6]  E. Koonin,et al.  Regeneration of Peroxiredoxins by p53-Regulated Sestrins, Homologs of Bacterial AhpD , 2004, Science.

[7]  S. Lowe,et al.  P53 Links Tumor Development to Cancer Therapy , 2007 .

[8]  A. Levine,et al.  The p53 pathway: positive and negative feedback loops , 2005, Oncogene.

[9]  Yong Liao,et al.  HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation , 2001, Nature Cell Biology.

[10]  T. Jacks,et al.  A subset of p53-deficient embryos exhibit exencephaly , 1995, Nature Genetics.

[11]  G. Wahl,et al.  Accelerated MDM2 auto‐degradation induced by DNA‐damage kinases is required for p53 activation , 2004, The EMBO journal.

[12]  V. Rotter,et al.  Mice with reduced levels of p53 protein exhibit the testicular giant-cell degenerative syndrome. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[13]  S. Thorgeirsson,et al.  Cyclin G Recruits PP 2 A to Dephosphorylate Mdm 2 , 2002 .

[14]  E. Appella,et al.  Detection of a transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[15]  Guillermina Lozano,et al.  Pirh2, a p53-Induced Ubiquitin-Protein Ligase, Promotes p53 Degradation , 2003, Cell.

[16]  L. Guarente,et al.  Negative control of p53 by Sir2alpha promotes cell survival under stress. , 2001, Cell.

[17]  Stephen J. Elledge,et al.  Mice Lacking p21 CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control , 1995, Cell.

[18]  J. Dausset,et al.  The p53-inducible TSAP6 gene product regulates apoptosis and the cell cycle and interacts with Nix and the Myt1 kinase , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[19]  Russell G. Jones,et al.  AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. , 2005, Molecular cell.

[20]  C. Prives,et al.  Regulation of p53 DNA Binding , 2007 .

[21]  K. Mitsumori,et al.  Modifying effects of ethinylestradiol but not methoxychlor on N-ethyl-N-nitrosourea-induced uterine carcinogenesis in heterozygous p53-deficient CBA mice. , 2000, Toxicological sciences : an official journal of the Society of Toxicology.

[22]  L. Donehower.  Does p53 affect organismal aging? , 2002, Journal of cellular physiology.

[23]  M. Oren,et al.  Decision making by p53: life, death and cancer , 2003, Cell Death and Differentiation.

[24]  D. Roop,et al.  Analysis of centrosome abnormalities and angiogenesis in epidermal‐targeted p53172H mutant and p53‐knockout mice after chemical carcinogenesis: Evidence for a gain of function , 1998, Molecular carcinogenesis.

[25]  D. Lane,et al.  Mdm2-Mediated NEDD8 Conjugation of p53 Inhibits Its Transcriptional Activity , 2004, Cell.

[26]  M. Papa,et al.  The R72P P53 mutation is associated with familial breast cancer in Jewish women , 2005, British Journal of Cancer.

[27]  Zhenhai Zhang,et al.  Loss of function of def selectively up-regulates Delta113p53 expression to arrest expansion growth of digestive organs in zebrafish. , 2005, Genes & development.

[28]  A. Dinh-Xuan,et al.  High levels of endogenous nitric oxide produced after burn injury in rats arrest activated T lymphocytes in the first G1 phase of the cell cycle and then induce their apoptosis. , 2005, Experimental cell research.

[29]  C. Kenyon.  The Plasticity of Aging: Insights from Long-Lived Mutants , 2005, Cell.

[30]  T. Soussi.  The p53 pathway and human cancer , 2005, The British journal of surgery.

[31]  Patrick Dowd,et al.  The ubiquitin ligase COP1 is a critical negative regulator of p53 , 2004, Nature.

[32]  H. Kinyamu,et al.  Estrogen Receptor-Dependent Proteasomal Degradation of the Glucocorticoid Receptor Is Coupled to an Increase in Mdm2 Protein Expression , 2003, Molecular and Cellular Biology.

[33]  D. Lane,et al.  T antigen is bound to a host protein in SY40-transformed cells , 1979, Nature.

[34]  Uri Alon,et al.  Dynamics of the p53-Mdm2 feedback loop in individual cells , 2004, Nature Genetics.

[35]  J. Ott,et al.  The p53MH algorithm and its application in detecting p53-responsive genes , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[36]  L. Mayo,et al.  A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[37]  K. Tsai,et al.  An intact HDM2 RING-finger domain is required for nuclear exclusion of p53 , 2000, Nature Cell Biology.

[38]  L. Strong.  General keynote: hereditary cancer: lessons from Li-Fraumeni syndrome. , 2003, Gynecologic oncology.

[39]  A. Khrunin,et al.  p53 polymorphisms in Russia and Belarus: correlation of the 2-1-1 haplotype frequency with longitude , 2005, Molecular Genetics and Genomics.

[40]  L. Guarente,et al.  Calorie Restriction— the SIR2 Connection , 2005, Cell.

[41]  A. Levine,et al.  p53 tumor suppressor protein regulates the levels of huntingtin gene expression , 2006, Oncogene.

[42]  M. Murphy,et al.  The codon 72 polymorphic variants of p53 have markedly different apoptotic potential , 2003, Nature Genetics.

[43]  A. Giaccia,et al.  The complexity of p53 modulation: emerging patterns from divergent signals. , 1998, Genes & development.

[44]  E. Appella,et al.  p53 Regulates the Expression of the Tumor Suppressor Gene Maspin* , 2000, The Journal of Biological Chemistry.

[45]  K. Dameron,et al.  Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. , 1994, Science.

[46]  B. Goud,et al.  TSAP6 Facilitates the Secretion of Translationally Controlled Tumor Protein/Histamine-releasing Factor via a Nonclassical Pathway* , 2004, Journal of Biological Chemistry.

[47]  Wei Gu,et al.  Ubiquitination, phosphorylation and acetylation: the molecular basis for p53 regulation. , 2003, Current opinion in cell biology.

[48]  M. Kaufman,et al.  High-frequency developmental abnormalities in p53-deficient mice , 1995, Current Biology.

[49]  A. Levine,et al.  Surfing the p53 network , 2000, Nature.

[50]  P. May,et al.  Simian virus 40-transformed cells express new species of proteins precipitable by anti-simian virus 40 tumor serum , 1979, Journal of virology.

[51]  M. Mergeay,et al.  Developmental abnormalities induced by X-irradiation in p53 deficient mice. , 2002, In vivo.

[52]  J. Otte,et al.  Differential regulation of plasminogen activator and inhibitor gene transcription by the tumor suppressor p53. , 1995, Nucleic acids research.

[53]  Yang Xu,et al.  Regulation of p53 responses by post-translational modifications , 2003, Cell Death and Differentiation.

[54]  Han You,et al.  Coordination and communication between the p53 and IGF-1-AKT-TOR signal transduction pathways. , 2006, Genes & development.

[55]  R. Wäsch,et al.  Anaphase-promoting complex-dependent proteolysis of cell cycle regulators and genomic instability of cancer cells , 2005, Oncogene.

[56]  U Alon,et al.  Generation of oscillations by the p53-Mdm2 feedback loop: a theoretical and experimental study. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[57]  Anindya Dutta,et al.  Erratum: A p53-dependent checkpoint pathway prevents rereplication (Molecular Cell (April 2003) 11 (997-1008)) , 2003 .

[58]  C. Prives,et al.  p53 linear diffusion along DNA requires its C terminus. , 2004, Molecular cell.

[59]  A. Levine,et al.  Nucleocytoplasmic shuttling of oncoprotein Hdm2 is required for Hdm2-mediated degradation of p53. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[60]  K. Kinzler,et al.  Definition of a consensus binding site for p53 , 1992, Nature Genetics.

[61]  James Brugarolas,et al.  Radiation-induced cell cycle arrest compromised by p21 deficiency , 1995, Nature.

[62]  Delin Chen,et al.  Negative Control of p53 by Sir2α Promotes Cell Survival under Stress , 2001, Cell.

[63]  S. Velasco-Miguel,et al.  Induction of the growth inhibitor IGF-binding protein 3 by p53 , 1995, Nature.

[64]  P. Meltzer,et al.  Amplification of a gene encoding a p53-associated protein in human sarcomas , 1992, Nature.

[65]  E. Appella,et al.  Post-translational modifications and activation of p53 by genotoxic stresses. , 2001, European journal of biochemistry.

[66]  Varda Rotter,et al.  Nitric oxide-induced cellular stress and p53 activation in chronic inflammation , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[67]  David P Lane,et al.  p53 isoforms can regulate p53 transcriptional activity. , 2005, Genes & development.

[68]  L. Vassilev,et al.  In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2 , 2004, Science.

[69]  Bernd W. Brandt,et al.  Variation in the human TP53 gene affects old age survival and cancer mortality1 , 2005, Experimental Gerontology.

[70]  J. Levine,et al.  Surfing the p53 network , 2000, Nature.

[71]  Martin Schuler,et al.  Direct Activation of Bax by p53 Mediates Mitochondrial Membrane Permeabilization and Apoptosis , 2004, Science.

[72]  A. Levine,et al.  Characterization of a 54K Dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells , 1979, Cell.

[73]  Valerie Reinke,et al.  Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53 , 2001, Nature Genetics.

[74]  A. Levine,et al.  A Single Nucleotide Polymorphism in the MDM2 Promoter Attenuates the p53 Tumor Suppressor Pathway and Accelerates Tumor Formation in Humans , 2004, Cell.

[75]  S. Thorgeirsson,et al.  Cyclin G recruits PP2A to dephosphorylate Mdm2. , 2002, Molecular cell.

[76]  A. Levine,et al.  The First Twenty-Five Years of p53 Research , 2007 .

[77]  D. Notterman,et al.  The transcriptional program following p53 activation. , 2000, Cold Spring Harbor symposia on quantitative biology.

[78]  F. McKeon,et al.  P53, P63, AND P73: INTERNECINE RELATIONS? , 2007 .

[79]  A. Yang,et al.  On the shoulders of giants: p63, p73 and the rise of p53. , 2002, Trends in genetics : TIG.

[80]  Guillermina Lozano,et al.  Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53 , 1995, Nature.

[81]  A. Gudkov,et al.  The role of p53 in determining sensitivity to radiotherapy , 2003, Nature Reviews Cancer.

[82]  A. Levine,et al.  The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation , 1992, Cell.

[83]  G. Blandino,et al.  P73, P63 and Mutant P53: Members of Protein Complexs Floating in Cancer Cells , 2007 .